查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1628054

眼科药物 2025-2035

Ophthalmic Drugs Market Report 2025-2035
出版日期: | 出版商: Visiongain | 英文 340 Pages | 商品交期: 最快1-2个工作天内

价格

预计到 2035 年全球眼科药物市场将以 7.2% 的复合年增长率成长。

全球眼科药物市场由于几个关键因素而经历强劲增长。青光眼、黄斑部病变、糖尿病视网膜病变和干眼症等眼部疾病的增加推动了对先进药物解决方案的需求。由于全球人口老化和生活方式的改变，这些疾病的发病率不断上升，从而增加了对创新药物的需求，这进一步加速了这一趋势。此外，由于製药公司正在大力投资研发以推出新的和增强的治疗方法，强大的眼科药物管道也帮助市场成长。这些积极的发展使得治疗更有针对性和更精准，增加了治疗选择并加速了市场发展势头。由于持续的技术创新和不断的进步，全球眼科药物市场预计未来将保持成长轨迹。

药物副作用可能对产业成长构成课题

外用药物可引起多种副作用，包括暂时视力模糊、过敏反应、视觉障碍、刺痛、灼热和搔痒。较不常见但较严重的副作用包括视力突然变化、严重头痛、管状视野、眼睛不适、眼睛后部疼痛或眼睛感染的迹象，如肿胀或分泌物。考虑到这些因素，副作用，尤其是与局部类固醇相关的副作用，可能会限制市场成长。

本报告调查了全球眼科药物市场，并提供了市场概况、影响市场成长和市场机会的因素分析、市场规模趋势和预测、各细分市场、地区/主要国家和竞争格局的详细分析。主要公司的现况及概况。

目录

第1章 报告概述

第 2 章执行摘要

第3章 市场概况

  • 主要发现
  • 市场动态
    • 市场驱动力
    • 市场阻碍因素
    • 市场机会
  • 新趋势
  • 波特五力分析
  • PEST分析
  • 近期批准

第4章眼科药品市场按类型分析

  • 主要发现
  • 市场吸引力指数
  • 市场规模趋势和预测
  • 处方药
  • 非处方药物
    • 市场规模趋势与预测：按地区
    • 市占率：按地区

第5章眼科药品市场依通路分析

  • 主要发现
  • 市场吸引力指数
  • 市场规模趋势和预测
  • 医院药房
  • 药店
  • 网上药店
    • 市场规模趋势与预测：按地区
    • 市占率：按地区

第6章眼科药物市场分析（依适应症）

  • 主要发现
  • 市场吸引力指数
  • 市场规模趋势和预测
  • 视网膜疾病
  • 感染/发炎/过敏
  • 眼睛干涩
  • 青光眼
  • 其他
    • 市场规模趋势与预测：按地区
    • 市占率：按地区

第7章眼科药物市场依给药途径分析

  • 主要发现
  • 市场吸引力指数
  • 市场规模趋势和预测
  • 外用药物
  • 肠外
    • 市场规模趋势与预测：按地区
    • 市占率：按地区

第8章眼科药品市场区域分析

  • 主要发现
  • 市场规模趋势和预测

第9章北美眼科药品市场分析

第10章欧洲眼科药品市场分析

第 11 章亚太眼科药品市场分析

第12章拉丁美洲眼科药品市场分析

第13章中东及非洲眼科药品市场分析

第14章 公司简介

  • Strategic Outlook
  • Novartis AG
  • Bayer AG
  • Pfizer Inc.
  • Bausch+Lomb Corporation
  • Santen Pharmaceutical Co., Ltd.
  • Johnson & Johnson Services, Inc.
  • Regeneron Pharmaceuticals Inc.
  • AbbVie Inc.
  • F. Hoffmann-La Roche Ltd
  • Teva Pharmaceutical Industries Ltd.
  • Apellis Pharmaceuticals
  • Novaliq GmbH
  • Alimera Sciences
  • EyeBio
  • SpliceBio
  • Breye Therapeutics ApS
  • Nicox
  • Alcon
  • Viatris Inc.
  • Sun Pharmaceutical Industries Ltd.

第 15 章概述与建议

  • Visiongain 的一般讨论
  • 对参与企业的建议
Product Code: PHA1364

The global Ophthalmic Drugs market is projected to grow at a CAGR of 7.2% by 2035.

The The Ophthalmic Drugs Market Report 2025-2035: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

The global ophthalmic drugs market is experiencing robust growth, driven by several key factors. Rising incidences of eye-related conditions such as glaucoma, macular degeneration, diabetic retinopathy, and dry eye syndrome are fuelling the demand for advanced pharmaceutical solutions. This trend is further supported by an aging global population and lifestyle changes that increase susceptibility to these conditions, underscoring the need for innovative drug options. A strong pipeline of new ophthalmic drugs is also bolstering market expansion, as pharmaceutical companies invest substantially in R&D to introduce enhanced and novel treatments. These active developments are set to deliver more targeted and precise therapies, improving treatment options and accelerating market momentum. With sustained innovation and continuous advancements, the global ophthalmic drugs market is expected to maintain its growth trajectory in the coming years.

Side Effects of Drugs Likely to Challenge Industry Growth

Topical ophthalmic drugs can cause a variety of side effects, including temporary vision cloudiness, allergic reactions, visual disturbances, and stinging, burning, or itching. Less common but more severe side effects include sudden vision changes, intense headaches, tunnel vision, eye discomfort, pain behind the eyes, and signs of an eye infection, such as swelling and discharge. As a result, adverse effects, particularly those associated with topical steroidal drugs, may limit market growth.

Addressing drug-related side effects in the ophthalmic drugs market, particularly in developing countries, necessitates a comprehensive strategy. This includes increasing healthcare accessibility, developing medical infrastructure, educating patients, reducing counterfeit drug circulation, and enacting stringent regulatory frameworks to ensure the safety and efficacy of ophthalmic treatments. Apellis Pharmaceuticals' drug pegcetacoplan, which was approved by the FDA for geographic atrophy (GA) secondary to age-related macular degeneration (AMD), has raised safety concerns due to instances of intraocular inflammation (IOI), according to the American Society of Retina Specialists (ASRS). As of April 2023, the ASRS Research and Safety in Therapeutics (ReST) Committee began tracking reports of IOI, some of which resulted in severe retinal vasculitis, occlusive retinal vasculopathy, or vision loss. On 16th January 2024, a retrospective analysis revealed 14 cases of retinal vasculitis among 13 patients following their first pegcetacoplan injection, with inflammation typically manifesting around 10.5 days after the injection. Notably, retinal veins were more affected than arteries, and 57% of impacted eyes had significant vision acuity (VA) loss, with two cases necessitating enucleation due to severe complications. In addition, 43% of cases showed anterior segment neovascularisation. These findings highlight critical safety issues, emphasising the importance of continuous monitoring and real-world safety analysis of pegcetacoplan in order to better assess and manage associated risks.

What Questions Should You Ask before Buying a Market Research Report?

  • How is the ophthalmic drugs market evolving?
  • What is driving and restraining the ophthalmic drugs market?
  • How will each ophthalmic drugs submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2035?
  • How will the market shares for each ophthalmic drugs submarket develop from 2025 to 2035?
  • What will be the main driver for the overall market from 2025 to 2035?
  • Will leading ophthalmic drugs markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
  • How will the market shares of the national markets change by 2035 and which geographical region will lead the market in 2035?
  • Who are the leading players and what are their prospects over the forecast period?
  • How will the industry evolve during the period between 2025 and 2035? What are the implications of ophthalmic drugs projects taking place now and over the next 10 years?
  • Is there a greater need for product commercialisation to further scale the ophthalmic drugs market?
  • Where is the ophthalmic drugs market heading and how can you ensure you are at the forefront of the market?
  • What are the best investment options for new product and service lines?
  • What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Ophthalmic Drugs Market today, and over the next 10 years:

  • Our 344-page report provides 129 tables, 178 charts/graphs exclusively to you.
  • The report highlights key lucrative areas in the industry so you can target them NOW.
  • It contains in-depth analysis of global, regional and national sales and growth.
  • It highlights for you the key successful trends, changes and revenue projections made by your competitors.
  • Forecasts to 2035 and other analyses reveal commercial prospects
  • In addition to revenue forecasting to 2035, our new study provides you with recent results, growth rates, and market shares.
  • You will find original analyses, with business outlooks and developments.
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising ophthalmic drugs prices and recent developments.

Segments Covered in the Report

  • Type
  • Prescription Drugs
  • OTC Drugs
  • Indication
  • Retinal Disorders
  • Infection/Inflammation/Allergy
  • Glaucoma
  • Dry Eye
  • Others
  • Route of Administration
  • Topical
  • Parenteral
  • Distribution Channel
  • Hospital Pharmacies
  • Drug Stores
  • Online Pharmacies

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 26 leading national markets:

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • Spain
  • UK
  • France
  • Italy
  • Netherlands
  • Switzerland
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Malaysia
  • Singapore
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Chile
  • Rest of Latin America
  • MEA
  • GCC
  • South Africa
  • Rest of MEA

The report also includes profiles and for some of the leading companies in the Ophthalmic Drugs Market 2025 to 2035, with a focus on this segment of these companies' operations.

  • Leading companies and the potential for market growth
  • AbbVie Inc.
  • Alcon
  • Alimera Sciences
  • Apellis Pharmaceuticals
  • Bausch + Lomb Corporation
  • Bayer AG
  • Breye Therapeutics ApS
  • EyeBio
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson Services, Inc.
  • Nicox
  • Novaliq GmbH
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Santen Pharmaceutical Co., Ltd.
  • SpliceBio
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.

Overall world revenue for ophthalmic drugs market, 2025 to 2035 in terms of value the market will surpass US$35.0 billion in 2025, our work calculates. We predict strong revenue growth through to 2035. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

  • How will the Ophthalmic Drugs Market, 2025 to 2035 report help you?
  • In summary, our 340+ page report provides you with the following knowledge:
  • Revenue forecasts to 2035 for Ophthalmic Drugs Market, 2025 to 2035 Market, with forecasts for type, distribution channel, indication, route of administration, each forecast at a global and regional level discover the industry's prospects, finding the most lucrative places for investments and revenues.
  • Revenue forecasts to 2035 for five regional and 26 key national markets See forecasts for the Ophthalmic Drugs Market, 2025 to 2035 market in North America, Europe, Asia-Pacific, Latin America and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
  • Prospects for established firms and those seeking to enter the market including company profiles for 21 of the major companies involved in the Ophthalmic Drugs Market, 2025 to 2035.
  • Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.
  • Information found nowhere else
  • With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the Ophthalmic Drugs Market, 2025 to 2035, market-leading companies. You will find data, trends and predictions.

Table of Contents

1 Report Overview

  • 1.1 Objectives of the Study
  • 1.2 Introduction to Ophthalmic Drugs Market
  • 1.3 What This Report Delivers
  • 1.4 Why You Should Read This Report
  • 1.5 Key Questions Answered by This Analytical Report
  • 1.6 Who is This Report for?
  • 1.7 Methodology
    • 1.7.1 Market Definitions
    • 1.7.2 Market Evaluation & Forecasting Methodology
    • 1.7.3 Data Validation
      • 1.7.3.1 Primary Research
      • 1.7.3.2 Secondary Research
  • 1.8 Frequently Asked Questions (FAQs)
  • 1.9 Associated Visiongain Reports
  • 1.10 About Visiongain

2 Executive Summary

3 Market Overview

  • 3.1 Key Findings
  • 3.2 Market Dynamics
    • 3.2.1 Market Driving Factors
      • 3.2.1.1 Rising Frequency and Occurrence of Eye-related Conditions
      • 3.2.1.2 Technological Advancements and Innovations
      • 3.2.1.3 Increasing Prevalence of Diabetes
      • 3.2.1.4 Presence of Strong Emerging Pipeline Drugs
    • 3.2.2 Market Restraining Factors
      • 3.2.2.1 Lack of Health Insurance in the Developing Countries
      • 3.2.2.2 Lack of Awareness Regarding the Available Treatment Options
      • 3.2.2.3 Side Effects of Drugs
      • 3.2.2.4 Patent Expiry of Blockbuster Drugs
      • 3.2.2.5 Impact of Elevated R&D Expenses and Patent Loss on Popular Pharmaceuticals
      • 3.2.2.6 Intensifying Competition in the Crowded Ophthalmic Drugs Market
    • 3.2.3 Market Opportunities
      • 3.2.3.1 Rise in Investment in Research and Development
      • 3.2.3.2 Rise in Geriatric Population
      • 3.2.3.3 Emergence of Digital Health Solutions and Telemedicine
      • 3.2.3.4 Growing Regulatory Support for Innovation in the Ophthalmic Sector
      • 3.2.3.5 E-Commerce and Online Pharmacies Unlock New Market Opportunities
  • 3.3 Emerging Trends
  • 3.4 Porter's Five Forces Analysis
    • 3.4.1 Bargaining Power of Suppliers
    • 3.4.2 Bargaining Power of Buyers
    • 3.4.3 Competitive Rivalry
    • 3.4.4 Threat of Substitutes
    • 3.4.5 Threat of New Entrants
  • 3.5 PEST Analysis
    • 3.5.1 Political
    • 3.5.2 Economical
    • 3.5.3 Social
    • 3.5.4 Technological
  • 3.6 Recent Approvals

4 Ophthalmic Drugs Market Analysis by Type

  • 4.1 Key Findings
  • 4.2 Type Segment: Market Attractiveness Index
  • 4.3 Ophthalmic Drugs Market Size Estimation and Forecast by Type
  • 4.4 Prescription Drugs
    • 4.4.1 Market Size by Region, 2025-2035 (US$ Billion)
    • 4.4.2 Market Share by Region, 2025 & 2035 (%)
  • 4.5 OTC Drugs
    • 4.5.1 Market Size by Region, 2025-2035 (US$ Billion)
    • 4.5.2 Market Share by Region, 2025 & 2035 (%)

5 Ophthalmic Drugs Market Analysis by Distribution Channel

  • 5.1 Key Findings
  • 5.2 Distribution Channel Segment: Market Attractiveness Index
  • 5.4 Ophthalmic Drugs Market Size Estimation and Forecast by Distribution Channel
  • 5.5 Hospital Pharmacies
    • 5.5.1 Market Size by Region, 2025-2035 (US$ Billion)
    • 5.5.2 Market Share by Region, 2025 & 2035 (%)
  • 5.6 Drug Stores
    • 5.6.1 Market Size by Region, 2025-2035 (US$ Billion)
    • 5.6.2 Market Share by Region, 2025 & 2035 (%)
  • 5.7 Online Pharmacies
    • 5.7.1 Market Size by Region, 2025-2035 (US$ Billion)
    • 5.7.2 Market Share by Region, 2025 & 2035 (%)

6 Ophthalmic Drugs Market Analysis by Indication

  • 6.1 Key Findings
  • 6.2 Indication Segment: Market Attractiveness Index
  • 6.3 Ophthalmic Drugs Market Size Estimation and Forecast by Indications
  • 6.4 Retinal Disorders
    • 6.4.1 Market Size by Region, 2025-2035 (US$ Billion)
    • 6.4.2 Market Share by Region, 2025 & 2035 (%)
  • 6.5 Infection/Inflammation/Allergy
    • 6.5.1 Market Size by Region, 2025-2035 (US$ Billion)
    • 6.5.2 Market Share by Region, 2025 & 2035 (%)
  • 6.6 Dry Eye
    • 6.6.1 Market Size by Region, 2025-2035 (US$ Billion)
    • 6.6.2 Market Share by Region, 2025 & 2035 (%)
  • 6.7 Glaucoma
    • 6.7.1 Market Size by Region, 2025-2035 (US$ Billion)
    • 6.7.2 Market Share by Region, 2025 & 2035 (%)
  • 6.8 Others
    • 6.8.1 Market Size by Region, 2025-2035 (US$ Billion)
    • 6.8.2 Market Share by Region, 2025 & 2035 (%)

7 Ophthalmic Drugs Market Analysis by Route of Administration

  • 7.1 Key Findings
  • 7.2 Route of Administration Segment: Market Attractiveness Index
  • 7.4 Ophthalmic Drugs Market Size Estimation and Forecast by Route of Administration
  • 7.5 Topical
    • 7.5.1 Market Size by Region, 2025-2035 (US$ Billion)
    • 7.5.2 Market Share by Region, 2025 & 2035 (%)
  • 7.6 Parenteral
    • 7.6.1 Market Size by Region, 2025-2035 (US$ Billion)
    • 7.6.2 Market Share by Region, 2025 & 2035 (%)

8 Ophthalmic Drugs Market Analysis by Region

  • 8.1 Key Findings
  • 8.2 Regional Market Size Estimation and Forecast

9 North America Ophthalmic Drugs Market Analysis

  • 9.1 Key Findings
  • 9.2 North America Ophthalmic Drugs Market Attractiveness Index
  • 9.3 North America Ophthalmic Drugs Market by Country, 2025, 2030 & 2035 (US$ Billion)
  • 9.4 North America Ophthalmic Drugs Market Size Estimation and Forecast by Country
  • 9.5 North America Ophthalmic Drugs Market Size Estimation and Forecast by Type
  • 9.6 North America Ophthalmic Drugs Market Size Estimation and Forecast by Distribution channel
  • 9.7 North America Ophthalmic Drugs Market Size Estimation and Forecast by Indications
  • 9.8 North America Ophthalmic Drugs Market Size Estimation and Forecast by Route of Administration
  • 9.9 U.S. Ophthalmic Drugs Market Analysis
  • 9.10 Canada Ophthalmic Drugs Market Analysis

10 Europe Ophthalmic Drugs Market Analysis

  • 10.1 Key Findings
  • 10.2 Europe Ophthalmic Drugs Market Attractiveness Index
  • 10.3 Europe Ophthalmic Drugs Market by Country, 2025, 2030 & 2035 (US$ Billion)
  • 10.5 Europe Ophthalmic Drugs Market Size Estimation and Forecast by Country
  • 10.6 Europe Ophthalmic Drugs Market Size Estimation and Forecast by Type
  • 10.7 Europe Ophthalmic Drugs Market Size Estimation and Forecast by Distribution Channel
  • 10.8 Europe Ophthalmic Drugs Market Size Estimation and Forecast by Indications
  • 10.9 Europe Ophthalmic Drugs Market Size Estimation and Forecast by Route of Administration
  • 10.10 Germany Ophthalmic Drugs Market Analysis
  • 10.11 France Ophthalmic Drugs Market Analysis
  • 10.12 UK Ophthalmic Drugs Market Analysis
  • 10.13 Italy Ophthalmic Drugs Market Analysis
  • 10.14 Spain Ophthalmic Drugs Market Analysis
  • 10.15 Netherlands Ophthalmic Drugs Market Analysis
  • 10.16 Switzerland Ophthalmic Drugs Market Analysis
  • 10.17 Rest of Europe Ophthalmic Drugs Market Analysis

11 Asia Pacific Ophthalmic Drugs Market Analysis

  • 11.1 Key Findings
  • 11.2 Asia Pacific Ophthalmic Drugs Market Attractiveness Index
  • 11.3 Asia Pacific Ophthalmic Drugs Market by Country, 2025, 2030 & 2035 (US$ Billion)
  • 11.4 Asia Pacific Ophthalmic Drugs Market Size Estimation and Forecast by Country
  • 11.5 Asia Pacific Ophthalmic Drugs Market Size Estimation and Forecast by Type
  • 11.6 Asia Pacific Ophthalmic Drugs Market Size Estimation and Forecast by Distribution Channel
  • 11.7 Asia Pacific Ophthalmic Drugs Market Size Estimation and Forecast by Indications
  • 11.9 Asia Pacific Ophthalmic Drugs Market Size Estimation and Forecast by Route of Administration
  • 11.10 Japan Ophthalmic Drugs Market Analysis
  • 11.11 China Ophthalmic Drugs Market Analysis
  • 11.12 India Ophthalmic Drugs Market Analysis
  • 11.13 Australia Ophthalmic Drugs Market Analysis
  • 11.14 South Korea Ophthalmic Drugs Market Analysis
  • 11.15 Malaysia Ophthalmic Drugs Market Analysis
  • 11.16 Singapore Ophthalmic Drugs Market Analysis
  • 11.17 Rest of Asia Pacific Ophthalmic Drugs Market Analysis

12 Latin America Ophthalmic Drugs Market Analysis

  • 12.1 Key Findings
  • 12.2 Latin America Ophthalmic Drugs Market Attractiveness Index
  • 12.3 Latin America Ophthalmic Drugs Market by Country, 2025, 2030 & 2035 (US$ Billion)
  • 12.4 Latin America Ophthalmic Drugs Market Size Estimation and Forecast by Country
  • 12.5 Latin America Ophthalmic Drugs Market Size Estimation and Forecast by Type
  • 12.6 Latin America Ophthalmic Drugs Market Size Estimation and Forecast by Distribution Channel
  • 12.7 Latin America Ophthalmic Drugs Market Size Estimation and Forecast by Indications
  • 12.8 Latin America Ophthalmic Drugs Market Size Estimation and Forecast by Route of Administration
  • 12.9 Brazil Ophthalmic Drugs Market Analysis
  • 12.10 Argentina Ophthalmic Drugs Market Analysis
  • 12.11 Mexico Ophthalmic Drugs Market Analysis
  • 12.12 Chile Ophthalmic Drugs Market Analysis
  • 12.13 Rest of Latin America Ophthalmic Drugs Market Analysis

13 MEA Ophthalmic Drugs Market Analysis

  • 13.1 Key Findings
  • 13.2 MEA Ophthalmic Drugs Market Attractiveness Index
  • 13.3 MEA Ophthalmic Drugs Market by Country, 2025, 2030 & 2035 (US$ Billion)
  • 13.5 MEA Ophthalmic Drugs Market Size Estimation and Forecast by Country
  • 13.6 MEA Ophthalmic Drugs Market Size Estimation and Forecast by Type
  • 13.7 MEA Ophthalmic Drugs Market Size Estimation and Forecast by Distribution Channel
  • 13.8 MEA Ophthalmic Drugs Market Size Estimation and Forecast by Indications
  • 13.9 MEA Ophthalmic Drugs Market Size Estimation and Forecast by Route of Administration
  • 13.10 GCC Ophthalmic Drugs Market Analysis
  • 13.11 South Africa Ophthalmic Drugs Market Analysis
  • 13.12 Rest of MEA Ophthalmic Drugs Market Analysis

14 Company Profiles

  • 14.1 Strategic Outlook
  • 14.2 Novartis AG
    • 14.2.1 Company Snapshot
    • 14.2.2 Company Overview
    • 14.2.3 Financial Analysis
      • 14.2.3.1 Net Revenue, 2018-2023
      • 14.2.3.2 Regional Market Shares, 2023
      • 14.2.3.3 R&D Expense, 2018-2023
    • 14.2.4 Product Benchmarking
    • 14.2.5 Strategic Outlook
  • 14.3 Bayer AG
    • 14.3.1 Company Snapshot
    • 14.3.2 Company Overview
    • 14.3.3 Financial Analysis
      • 14.3.3.1 Net Revenue, 2018-2023
      • 14.3.3.2 Regional Market Shares, 2023
      • 14.3.3.3 Business Segment Market Shares, 2023
      • 14.3.3.4 R&D Expense, 2018-2023
    • 14.3.4 Product Benchmarking
    • 14.3.5 Strategic Outlook
  • 14.4 Pfizer Inc.
    • 14.4.1 Company Snapshot
    • 14.4.2 Company Overview
    • 14.4.3 Financial Analysis
      • 14.4.3.1 Revenue, 2018-2023
      • 14.4.3.2 Regional Market Shares, 2023
      • 14.4.3.3 Business Segment Market Shares, 2023
      • 14.4.3.4 R&D Expense, 2018-2023
    • 14.4.4 Product Benchmarking
  • 14.5 Bausch + Lomb Corporation
    • 14.5.1 Company Snapshot
    • 14.5.2 Company Overview
    • 14.5.3 Financial Analysis
      • 14.5.3.1 Revenue, 2020-2023
      • 14.5.3.2 R&D Expense, 2020-2023
    • 14.5.4 Product Benchmarking
    • 14.5.5 Strategic Outlook
  • 14.6 Santen Pharmaceutical Co., Ltd.
    • 14.6.1 Company Snapshot
    • 14.6.2 Company Overview
    • 14.6.3 Financial Analysis
      • 14.6.3.1 Revenue, 2018-2023
      • 14.6.3.2 Regional Market Shares, 2023
    • 14.6.4 Product Benchmarking
    • 14.6.5 Strategic Outlook
  • 14.7 Johnson & Johnson Services, Inc.
    • 14.7.1 Company Snapshot
    • 14.7.2 Company Overview
    • 14.7.3 Financial Analysis
      • 14.7.3.1 Revenue, 2018-2023
      • 14.7.3.2 Regional Market Shares, 2023
      • 14.7.3.3 Business Segment Market Shares, 2023
      • 14.7.3.4 R&D Expense, 2018-2023
    • 14.7.4 Product Benchmarking
    • 14.7.5 Strategic Outlook
  • 14.9 Regeneron Pharmaceuticals Inc.
    • 14.9.1 Company Snapshot
    • 14.9.2 Company Overview
    • 14.9.3 Financial Analysis
      • 14.9.3.1 Revenue, 2018-2023
      • 14.9.3.2 R&D Expense, 2018-2023
    • 14.9.4 Product Benchmarking
    • 14.9.5 Strategic Outlook
  • 14.10 AbbVie Inc.
    • 14.10.1 Company Snapshot
    • 14.10.2 Company Overview
    • 14.10.3 Financial Analysis
      • 14.10.3.1 Revenue, 2018-2023
      • 14.10.3.2 Regional Market Shares, 2023
      • 14.10.3.3 Business Segment Market Shares, 2023
      • 14.10.3.4 R&D Expense, 2018-2023
    • 14.10.4 Product Benchmarking
    • 14.10.5 Strategic Outlook
  • 14.11 F. Hoffmann-La Roche Ltd
    • 14.11.1 Company Snapshot
    • 14.11.2 Company Overview
    • 14.11.3 Financial Analysis
      • 14.11.3.1 Revenue, 2018-2023
      • 14.11.3.2 Business Segment Market Shares, 2023
      • 14.11.3.3 R&D Expense, 2018-2023
    • 14.11.4 Product Benchmarking
    • 14.11.5 Strategic Outlook
  • 14.12 Teva Pharmaceutical Industries Ltd.
    • 14.12.1 Company Snapshot
    • 14.12.2 Company Overview
    • 14.12.3 Financial Analysis
      • 14.12.3.1 Revenue, 2018-2023
      • 14.12.3.2 Regional Market Shares, 2023
      • 14.12.3.3 R&D Expense, 2018-2023
    • 14.12.4 Product Benchmarking
    • 14.12.5 Strategic Outlook
  • 14.13 Apellis Pharmaceuticals
    • 14.13.1 Company Snapshot
    • 14.13.2 Company Overview
    • 14.13.3 Financial Analysis
      • 14.13.3.1 Revenue, 2020-2023
    • 14.13.4 Product Benchmarking
    • 14.13.5 Strategic Outlook
  • 14.14 Novaliq GmbH
    • 14.14.1 Company Snapshot
    • 14.14.2 Company Overview
    • 14.14.3 Product Benchmarking
    • 14.14.4 Strategic Outlook
  • 14.15 Alimera Sciences
    • 14.15.1 Company Snapshot
    • 14.15.2 Company Overview
    • 14.15.3 Financial Analysis
      • 14.15.3.1 Revenue, 2018-2023
      • 14.15.3.2 R&D Expense, 2018-2023
      • 14.15.3.3 Regional Market Shares, 2023
    • 14.15.4 Product Benchmarking
    • 14.15.5 Strategic Outlook
  • 14.16 EyeBio
    • 14.16.1 Company Snapshot
    • 14.16.2 Company Overview
    • 14.16.3 Product Benchmarking
    • 14.16.4 Strategic Outlook
  • 14.17 SpliceBio
    • 14.17.1 Company Snapshot
    • 14.17.2 Company Overview
    • 14.17.3 Product Benchmarking
    • 14.17.4 Strategic Outlook
  • 14.18 Breye Therapeutics ApS
    • 14.18.1 Company Snapshot
    • 14.18.2 Company Overview
    • 14.18.3 Product Benchmarking
    • 14.18.4 Strategic Outlook
  • 14.19 Nicox
    • 14.19.1 Company Snapshot
    • 14.19.2 Company Overview
    • 14.19.3 Financial Analysis
      • 14.19.3.1 Net Revenue, 2019-2023
    • 14.19.5 Product Benchmarking
    • 14.19.6 Strategic Outlook
  • 14.20 Alcon
    • 14.20.1 Company Snapshot
    • 14.20.2 Company Overview
    • 14.20.3 Financial Analysis
      • 14.20.3.1 Net Revenue, 2018-2023
      • 14.20.3.2 Business Segment Market Shares, 2023
      • 14.20.3.3 Regional Market Shares, 2023
      • 14.20.3.4 R&D Expense, 2018-2023
    • 14.20.4 Product Benchmarking
    • 14.20.5 Strategic Outlook
  • 14.21 Viatris Inc.
    • 14.21.1 Company Snapshot
    • 14.21.2 Company Overview
    • 14.21.3 Financial Analysis
      • 14.21.3.1 Net Revenue, 2018-2023
      • 14.21.3.2 Regional Market Shares, 2023
      • 14.21.3.3 R&D Expense, 2018-2023
    • 14.21.4 Product Benchmarking
    • 14.21.5 Strategic Outlook
  • 14.22 Sun Pharmaceutical Industries Ltd.
    • 14.22.1 Company Snapshot
    • 14.22.2 Company Overview
    • 14.22.3 Financial Analysis
      • 14.22.3.1 Net Revenue, 2018-2023
    • 14.22.4 Product Benchmarking

15 Conclusion and Recommendations

  • 15.1 Concluding Remarks from Visiongain
  • 15.2 Recommendations for Market Players

List of Tables

  • Table 1 Ophthalmic Drugs Market Snapshot, 2025 & 2035 (US$ billion, CAGR %)
  • Table 2 Ophthalmic Drugs Market: Product Pipeline
  • Table 3 Ophthalmic Drugs Market Forecast by Indications, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 4 Prescription Drugs Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
  • Table 5 OTC Drugs Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
  • Table 6 Ophthalmic Drugs Market Forecast by Distribution Channel, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 7 Hospital Pharmacies Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
  • Table 8 Drug Stores Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
  • Table 9 Online Pharmacies Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
  • Table 10 Ophthalmic Drugs Market Forecast by Indications, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 11 Retinal Disorders Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
  • Table 12 Infection/Inflammation/Allergy Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
  • Table 13 Dry Eye Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
  • Table 14 Glaucoma Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
  • Table 15 Others Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
  • Table 16 Ophthalmic Drugs Market Forecast by Indications, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 17 Topical Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
  • Table 18 Parenteral Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
  • Table 19 Ophthalmic Drugs Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 20 North America Ophthalmic Drugs Market Forecast by Country, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 21 North America Ophthalmic Drugs Market Forecast by Indications, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 22 North America Ophthalmic Drugs Market Forecast by Distribution Channel, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 23 North America Ophthalmic Drugs Market Forecast by Indications, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 24 North America Ophthalmic Drugs Market Forecast by Indications, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 25 U.S. Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
  • Table 26 Canada Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
  • Table 27 Europe Ophthalmic Drugs Market Forecast by Country, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 28 Europe Ophthalmic Drugs Market Forecast by Indications, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 29 Europe Ophthalmic Drugs Market Forecast by Distribution Channel, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 30 Europe Ophthalmic Drugs Market Forecast by Indications, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 31 Europe Ophthalmic Drugs Market Forecast by Indications, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 32 Germany Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
  • Table 33 France Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
  • Table 34 UK Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
  • Table 35 Italy Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
  • Table 36 Spain Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
  • Table 37 Netherlands Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
  • Table 38 Switzerland Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
  • Table 39 Rest of Europe Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
  • Table 40 Asia Pacific Ophthalmic Drugs Market Forecast by Country, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 41 Asia Pacific Ophthalmic Drugs Market Forecast by Indications, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 42 Asia Pacific Ophthalmic Drugs Market Forecast by Distribution Channel, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 43 Asia Pacific Ophthalmic Drugs Market Forecast by Indications, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 44 Asia Pacific Ophthalmic Drugs Market Forecast by Indications, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 45 Japan Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
  • Table 46 China Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
  • Table 47 India Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
  • Table 48 Australia Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
  • Table 49 South Korea Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
  • Table 50 Malaysia Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
  • Table 51 Singapore Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
  • Table 52 Rest of Asia Pacific Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
  • Table 53 Latin America Ophthalmic Drugs Market Forecast by Country, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 54 Latin America Ophthalmic Drugs Market Forecast by Indications, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 55 Latin America Ophthalmic Drugs Market Forecast by Distribution Channel, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 56 Latin America Ophthalmic Drugs Market Forecast by Indications, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 57 Latin America Ophthalmic Drugs Market Forecast by Indications, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 58 Brazil Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
  • Table 59 Argentina Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
  • Table 60 Mexico Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
  • Table 61 Chile Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
  • Table 62 Rest of Latin America Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
  • Table 63 MEA Ophthalmic Drugs Market Forecast by Country, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 64 MEA Ophthalmic Drugs Market Forecast by Indications, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 65 MEA Ophthalmic Drugs Market Forecast by Distribution Channel, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 66 MEA Ophthalmic Drugs Market Forecast by Indications, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 67 MEA Ophthalmic Drugs Market Forecast by Indications, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 68 GCC Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
  • Table 69 South Africa Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
  • Table 70 Rest of MEA Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
  • Table 71 Strategic Outlook
  • Table 72 Novartis AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 73 Novartis AG: Product Benchmarking
  • Table 74 Novartis AG: Strategic Outlook
  • Table 75 Bayer AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 76 Bayer AG: Product Benchmarking
  • Table 77 Bayer AG: Strategic Outlook
  • Table 78 Pfizer Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 79 Pfizer Inc.: Product Benchmarking
  • Table 80 Bausch + Lomb Corporation: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 81 Bausch + Lomb Corporation: Product Benchmarking
  • Table 82 Bausch + Lomb Corporation: Strategic Outlook
  • Table 83 Santen Pharmaceutical Co., Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 84 Santen Pharmaceutical Co., Ltd.: Product Benchmarking
  • Table 85 Santen Pharmaceutical Co., Ltd.: Strategic Outlook
  • Table 86 Johnson & Johnson Services Inc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 87 Johnson & Johnson Private Limited: Product Benchmarking
  • Table 88 Johnson & Johnson Private Limited: Strategic Outlook
  • Table 89 Regeneron Pharmaceuticals Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 90 Regeneron Pharmaceuticals Inc.: Product Benchmarking
  • Table 91 Regeneron Pharmaceuticals Inc.: Strategic Outlook
  • Table 92 AbbVie Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 93 AbbVie Inc.: Product Benchmarking
  • Table 94 AbbVie Inc.: Strategic Outlook
  • Table 95 F. Hoffmann-La Roche Ltd: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 96 F. Hoffmann-La Roche Ltd: Product Benchmarking
  • Table 97 F. Hoffmann-La Roche Ltd: Strategic Outlook
  • Table 98 Teva Pharmaceutical Industries Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 99 Teva Pharmaceutical Industries Ltd.: Product Benchmarking
  • Table 100 Teva Pharmaceutical Industries Ltd.: Strategic Outlook
  • Table 101 Apellis Pharmaceuticals: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 102 Apellis Pharmaceuticals: Product Benchmarking
  • Table 103 Apellis Pharmaceuticals: Strategic Outlook
  • Table 104 Novaliq GmbH: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 105 Novaliq GmbH.: Product Benchmarking
  • Table 106 Novaliq GmbH: Strategic Outlook
  • Table 107 Alimera Sciences: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 108 Alimera Sciences: Product Benchmarking
  • Table 109 Alimera Sciences: Strategic Outlook
  • Table 110 EyeBio: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 111 EyeBio: Product Benchmarking
  • Table 112 EyeBio: Strategic Outlook
  • Table 113 SpliceBio: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 114 SpliceBio: Product Benchmarking
  • Table 115 SpliceBio: Strategic Outlook
  • Table 116 Breye Therapeutics ApS: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 117 Breye Therapeutics ApS: Product Benchmarking
  • Table 118 Breye Therapeutics ApS: Strategic Outlook
  • Table 119 Nicox: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 120 Nicox: Product Benchmarking
  • Table 121 Nicox: Strategic Outlook
  • Table 122 Alcon: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 123 Alcon: Product Benchmarking
  • Table 124 Alcon: Strategic Outlook
  • Table 125 Viatris Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 126 Viatris Inc.: Product Benchmarking
  • Table 127 Viatris Inc.: Strategic Outlook
  • Table 128 Sun Pharmaceutical Industries Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 129 Sun Pharmaceutical Industries Ltd.: Product Benchmarking

List of Figures

  • Figure 1 Ophthalmic Drugs Market Segmentation
  • Figure 2 Ophthalmic Drugs Market by Type: Market Attractiveness Index
  • Figure 3 Ophthalmic Drugs Market Forecast by Distribution Channel: Market Attractiveness Index
  • Figure 4 Ophthalmic Drugs Market Forecast by Indications: Market Attractiveness Index
  • Figure 5 Ophthalmic Drugs Market Forecast by Route of Administration: Market Attractiveness Index
  • Figure 6 Ophthalmic Drugs Market Attractiveness Index by Region
  • Figure 7 Ophthalmic Drugs Market: Market Dynamics
  • Figure 8 Ophthalmic Drugs Market: Porter's Five Forces Analysis
  • Figure 9 Ophthalmic Drugs Market: PEST Analysis
  • Figure 10 Ophthalmic Drugs Market Forecast by Type: Market Attractiveness Index
  • Figure 11 Ophthalmic Drugs Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
  • Figure 12 Ophthalmic Drugs Market Share Forecast by Type, 2025, 2030, 2035 (%)
  • Figure 13 Prescription Drugs Market Forecast by Region, 2025-2035 (US$ Billion)
  • Figure 14 Prescription Drugs Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 15 OTC Drugs Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • Figure 16 OTC Drugs Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 17 Ophthalmic Drugs Market Forecast by Distribution Channel: Market Attractiveness Index
  • Figure 18 Ophthalmic Drugs Market Forecast By Distribution Channel, 2025-2035 (US$ Billion, AGR %)
  • Figure 19 Ophthalmic Drugs Market Share Forecast by Distribution Channel, 2025, 2030, 2035 (%)
  • Figure 20 Hospital Pharmacies Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • Figure 21 Hospital Pharmacies Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 22 Drug Stores Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • Figure 23 Drug Stores Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 24 Online Pharmacies Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • Figure 25 Online Pharmacies Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 26 Ophthalmic Drugs Market Forecast by Indication: Market Attractiveness Index
  • Figure 27 Ophthalmic Drugs Market Forecast By Indications, 2025-2035 (US$ Billion, AGR %)
  • Figure 28 Ophthalmic Drugs Market Share Forecast by Indications, 2025, 2030, 2035 (%)
  • Figure 29 Retinal Disorders Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • Figure 30 Retinal Disorders Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 31 Infection/Inflammation/Allergy Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • Figure 32 Infection/Inflammation/Allergy Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 33 Dry Eye Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • Figure 34 Dry Eye Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 35 Glaucoma Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • Figure 36 Glaucoma Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 37 Others Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • Figure 38 Others Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 39 Ophthalmic Drugs Market Forecast by Route of Administration: Market Attractiveness Index
  • Figure 40 Ophthalmic Drugs Market Forecast by Route of Administration, 2025-2035 (US$ Billion, AGR %)
  • Figure 41 Ophthalmic Drugs Market Share Forecast by Route of administration, 2025, 2030, 2035 (%)
  • Figure 42 Topical Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • Figure 43 Topical Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 44 Parenteral Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • Figure 45 Parenteral Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 46 Ophthalmic Drugs Market Forecast by Region 2025 & 2035 (Revenue, CAGR%)
  • Figure 47 Ophthalmic Drugs Market Share Forecast by Region 2025, 2030, 2035 (%)
  • Figure 48 Ophthalmic Drugs Market by Region, 2025-2035 (US$ Billion, AGR (%), CAGR (%))
  • Figure 49 North America Ophthalmic Drugs Market Attractiveness Index
  • Figure 50 North America Ophthalmic Drugs Market by Region, 2025, 2030 & 2035 (US$ Billion)
  • Figure 51 North America Ophthalmic Drugs Market Forecast by Country, 2025-2035 (US$ Billion, AGR %)
  • Figure 52 North America Ophthalmic Drugs Market Share Forecast by Country, 2025 & 2035 (%)
  • Figure 53 North America Ophthalmic Drugs Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
  • Figure 54 North America Ophthalmic Drugs Market Share Forecast by Type, 2025 & 2035 (%)
  • Figure 55 North America Ophthalmic Drugs Market Forecast by Distribution Channel, 2025-2035 (US$ Billion
  • Figure 56 North America Ophthalmic Drugs Market Share Forecast by Distribution Channel, 2025 & 2035 (%)
  • Figure 57 North America Ophthalmic Drugs Market Forecast by Indications, 2025-2035 (US$ Billion, AGR %)
  • Figure 58 North America Ophthalmic Drugs Market Share Forecast by Indications, 2025 & 2035 (%)
  • Figure 59 North America Ophthalmic Drugs Market Forecast by Route of Administration, 2025-2035 (US$ Billion, AGR %)
  • Figure 60 North America Ophthalmic Drugs Market Share Forecast by Route of Administration, 2025 & 2035 (%)
  • Figure 61 U.S. Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 62 Canada Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 63 Europe Ophthalmic Drugs Market Attractiveness Index
  • Figure 64 Europe Ophthalmic Drugs Market by Region, 2025, 2030 & 2035 (US$ Billion)
  • Figure 65 Europe Ophthalmic Drugs Market Forecast by Country, 2025-2035 (US$ Billion, AGR %)
  • Figure 66 Europe Ophthalmic Drugs Market Share Forecast by Country, 2025 & 2035 (%)
  • Figure 67 Europe Ophthalmic Drugs Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
  • Figure 68 Europe Ophthalmic Drugs Market Share Forecast by Type, 2025 & 2035 (%)
  • Figure 69 Europe Ophthalmic Drugs Market Forecast by Distribution Channel, 2025-2035 (US$ Billion
  • Figure 70 Europe Ophthalmic Drugs Market Share Forecast by Distribution Channel, 2025 & 2035 (%)
  • Figure 71 Europe Ophthalmic Drugs Market Forecast by Indications, 2025-2035 (US$ Billion, AGR %)
  • Figure 72 Europe Ophthalmic Drugs Market Share Forecast by Indications, 2025 & 2035 (%)
  • Figure 73 Europe Ophthalmic Drugs Market Forecast by Route of Administration, 2025-2035 (US$ Billion, AGR %)
  • Figure 74 Europe Ophthalmic Drugs Market Share Forecast by Route of Administration, 2025 & 2035 (%)
  • Figure 75 Germany Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 76 France Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 77 UK Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 78 Italy Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 79 Spain Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 80 Netherlands Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 81 Switzerland Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 82 Rest of Europe Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 83 Asia Pacific Ophthalmic Drugs Market Attractiveness Index
  • Figure 84 Asia Pacific Ophthalmic Drugs Market by Region, 2025, 2030 & 2035 (US$ Billion)
  • Figure 85 Asia Pacific Op